Valneva SE (VLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Valneva SE (VLA) has a cash flow conversion efficiency ratio of -0.058x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.43 Million ≈ $-5.18 Million USD) by net assets (€76.70 Million ≈ $89.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VLA stock market capitalisation for the company's overall valuation and market capitalisation.
Valneva SE - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Valneva SE's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Valneva SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valneva SE ranked by their cash flow conversion efficiency. Explore VLA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TWC Enterprises Ltd
TO:TWC
|
0.081x |
|
Hume Industries Berhad
KLSE:5000
|
0.099x |
|
Bénéteau S.A.
PA:BEN
|
0.192x |
|
Suzhou Alton Electrical & Mechanical Industry Co. Ltd.
SHE:301187
|
-0.070x |
|
CapitaLand Malaysia Mall Trust
KLSE:5180
|
0.021x |
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
0.022x |
|
IBEX Ltd
NASDAQ:IBEX
|
0.074x |
|
SAMPYO Cement Co. Ltd
KQ:038500
|
0.061x |
Annual Cash Flow Conversion Efficiency for Valneva SE (2005–2025)
The table below shows the annual cash flow conversion efficiency of Valneva SE from 2005 to 2025. View VLA share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €106.17 Million ≈ $124.12 Million |
€-52.89 Million ≈ $-61.84 Million |
-0.498x | -34.34% |
| 2024-12-31 | €181.25 Million ≈ $211.90 Million |
€-67.22 Million ≈ $-78.58 Million |
-0.371x | +76.54% |
| 2023-12-31 | €128.25 Million ≈ $149.93 Million |
€-202.74 Million ≈ $-237.03 Million |
-1.581x | -41.63% |
| 2022-12-31 | €219.80 Million ≈ $256.97 Million |
€-245.34 Million ≈ $-286.83 Million |
-1.116x | -347.60% |
| 2021-12-31 | €170.58 Million ≈ $199.43 Million |
€76.90 Million ≈ $89.91 Million |
0.451x | -74.66% |
| 2020-12-31 | €77.42 Million ≈ $90.51 Million |
€137.74 Million ≈ $161.03 Million |
1.779x | +4248.79% |
| 2019-12-31 | €135.15 Million ≈ $158.01 Million |
€5.53 Million ≈ $6.46 Million |
0.041x | -64.08% |
| 2018-12-31 | €143.19 Million ≈ $167.40 Million |
€16.31 Million ≈ $19.06 Million |
0.114x | -17.74% |
| 2017-12-31 | €92.67 Million ≈ $108.34 Million |
€12.83 Million ≈ $15.00 Million |
0.138x | +112.93% |
| 2016-12-31 | €100.05 Million ≈ $116.97 Million |
€6.50 Million ≈ $7.61 Million |
0.065x | +138.56% |
| 2015-12-31 | €144.34 Million ≈ $168.74 Million |
€-24.33 Million ≈ $-28.45 Million |
-0.169x | -40.39% |
| 2014-12-31 | €124.44 Million ≈ $145.49 Million |
€-14.94 Million ≈ $-17.47 Million |
-0.120x | +17.21% |
| 2013-12-31 | €144.11 Million ≈ $168.48 Million |
€-20.90 Million ≈ $-24.44 Million |
-0.145x | +71.26% |
| 2012-12-31 | €26.19 Million ≈ $30.62 Million |
€-13.22 Million ≈ $-15.46 Million |
-0.505x | -135.82% |
| 2011-12-31 | €40.45 Million ≈ $47.28 Million |
€-8.66 Million ≈ $-10.12 Million |
-0.214x | -200.52% |
| 2010-12-31 | €44.29 Million ≈ $51.78 Million |
€-3.15 Million ≈ $-3.69 Million |
-0.071x | -270.86% |
| 2009-12-31 | €22.53 Million ≈ $26.34 Million |
€939.00K ≈ $1.10 Million |
0.042x | +162.04% |
| 2008-12-31 | €27.42 Million ≈ $32.05 Million |
€-1.84 Million ≈ $-2.15 Million |
-0.067x | +45.33% |
| 2007-12-31 | €29.01 Million ≈ $33.92 Million |
€-3.56 Million ≈ $-4.17 Million |
-0.123x | +79.07% |
| 2006-12-31 | €4.66 Million ≈ $5.45 Million |
€-2.73 Million ≈ $-3.20 Million |
-0.587x | -511.87% |
| 2005-12-31 | €4.78 Million ≈ $5.59 Million |
€681.00K ≈ $796.16K |
0.143x | -- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more